title: Pilot study of FPPRGD2 for imaging α(v)β(3) integrin--how integral are integrins?
abstract: Mittra et al (1) describe a new positron emission tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropionyl labeled PEGylated dimeric RGD peptide (FPPRGD2), a marker of α(v)β(3) integrin expression, which they tested in fi ve healthy volunteers. No adverse events were encountered, and the biodistribution suggested both a renal and a hepatobiliary excretory route. This early safety testing paves the way for future studies of patients with cancer who are undergoing antiangiogenic therapies. (18)F-FPPRGD2 represents one of several integrin imaging agents that are moving closer to clinical reality.
authors.affiliation: Molecular Imaging Program National Cancer Institute 10 Center Dr Building 10, Room B3B69F Bethesda, MD 20892, USA. pchoyke@nih.gov
authors.forename: Peter L
authors.initials: PL
authors.lastname: Choyke
mesh_terms: D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics*; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D009842:Oligopeptides / Q000493:pharmacokinetics*; D009928:Organ Specificity; D010865:Pilot Projects; D049268:Positron-Emission Tomography / Q000379:methods*; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D005462:Fluorine Radioisotopes; D039302:Integrin alphaVbeta3; D009842:Oligopeptides; D019275:Radiopharmaceuticals; C047981:arginyl-glycyl-aspartic acid